Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward
(2018) In International Journal of COPD 13. p.231-235- Abstract
Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b03790b9-5bad-4164-b475-8aa470e077b7
- author
- Ekström, Magnus LU and Ringbaek, Thomas
- organization
- publishing date
- 2018-01-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COPD, Hypoxemia, Oxygen therapy, Survival
- in
- International Journal of COPD
- volume
- 13
- pages
- 5 pages
- publisher
- Dove Medical Press Ltd.
- external identifiers
-
- pmid:29386891
- scopus:85040923967
- ISSN
- 1176-9106
- DOI
- 10.2147/COPD.S148673
- language
- English
- LU publication?
- yes
- id
- b03790b9-5bad-4164-b475-8aa470e077b7
- date added to LUP
- 2018-02-23 18:43:02
- date last changed
- 2024-07-08 09:55:55
@article{b03790b9-5bad-4164-b475-8aa470e077b7, abstract = {{<p>Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia.</p>}}, author = {{Ekström, Magnus and Ringbaek, Thomas}}, issn = {{1176-9106}}, keywords = {{COPD; Hypoxemia; Oxygen therapy; Survival}}, language = {{eng}}, month = {{01}}, pages = {{231--235}}, publisher = {{Dove Medical Press Ltd.}}, series = {{International Journal of COPD}}, title = {{Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward}}, url = {{http://dx.doi.org/10.2147/COPD.S148673}}, doi = {{10.2147/COPD.S148673}}, volume = {{13}}, year = {{2018}}, }